Table 1. Patient Demographics.
| Variable | Patients (%) | |
|---|---|---|
| Gender | Male | 77 (67) |
| Female | 38 (33) | |
| Race | White | 59 (51) |
| Black | 48 (42) | |
| Hispanic | 6 (5) | |
| Other | 2 (2) | |
| Age at Transplant | 0 – 5 | 26 (23) |
| 6 – 12 | 21(18) | |
| ≥ 13 | 68 (59) | |
| Donor Source | Living | 62 (54) |
| Deceased | 53 (46) | |
| D/R CMV Status | D−/R− | 28 (24) |
| D−/R+ | 5 (4) | |
| D+/R− | 39 (34) | |
| D+/R+ | 26 (23) | |
| At least one missing | 17 (15) | |
| Post-transplant Antiviral Prophylaxis | Valganciclovir | 73 (63) |
| Ganciclovir | 12 (10) | |
| Acyclovir | 22 (19) | |
| Mixed | 3 (3) | |
| Unknown | 5 (4) | |
| Underlying Diagnosis | Genetic/Structural | 90 (78) |
| Immune-mediated | 25 (22) | |
| Transplant Number | First | 108 (94) |
| Second or more | 7 (6) | |
| Neutropenia During Test Period | ANC < 1000/mm3 | 20 (17) |
| Antiviral Treatment During Test Period* | 11 (10) | |
| Received Immunosuppressive Agents Other Than Tacrolimus or Mycophenolate Mofetil During Test Period |
Sirolimus | 17 (15) |
| Cyclosporine | 3 (3) | |
| Azathioprine | 7 (6) | |
| More than 1 | 1 (1) | |
*
Antiviral treatment for CMV infection given at any point following transplant, either preemptively or for disease, with intravenous ganciclovir following approved dosing, or oral valganciclovir according to our center protocol, all adjusted for creatinine clearance.